دورية أكاديمية
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.
| العنوان: | National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. |
|---|---|
| المؤلفون: | Kim MM; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: michekim@med.umich.edu., Mehta MP; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Smart DK; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Steeg PS; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Hong JA; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Espey MG; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Prasanna PG; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Crandon L; Touch4Life, Clarksville, MD, USA., Hodgdon C; GRASP, Baltimore, MD, USA., Kozak N; Santa Maria, CA, USA., Armstrong TS; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Morikawa A; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Willmarth N; American Brain Tumor Association, Chicago, IL, USA., Tanner K; National Brain Tumor Society, Newton, MA, USA., Boire A; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gephart MH; Department of Neurosurgery, Stanford University, Stanford, CA, USA., Margolin KA; St John's Cancer Institute, Santa Monica, CA, USA., Hattangadi-Gluth J; Department of Radiation Oncology, University of California San Diego Health, La Jolla, CA, USA., Tawbi H; Department of Melanoma Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Trifiletti DM; Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA., Chung C; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Basu-Roy U; LUNGevity Foundation, Chicago, IL, USA., Burns R; Melanoma Research Foundation, Washington, DC, USA., Oliva ICG; Department of Melanoma Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aizer AA; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA., Anders CK; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Davis J; The Radiosurgery Society, San Jose, CA, USA., Ahluwalia MS; Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Chiang V; Department of Neurosurgery and Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA., Li J; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kotecha R; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Formenti SC; Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA., Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Gondi V; Department of Radiation Oncology, Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, IL, USA., Sperduto PW; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA., Barnholtz-Sloan JS; Informatics and Data Science Program, Center for Biomedical Informatics and Information Technology, Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA., Rodon J; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Khasraw M; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA., Yeboa DN; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brastianos PK; Division of Hematology/Oncology and Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Galanis E; Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA., Coleman CN; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Ahmed MM; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA. Electronic address: ahmedmm@mail.nih.gov. |
| المصدر: | The Lancet. Oncology [Lancet Oncol] 2023 Aug; Vol. 24 (8), pp. e344-e354. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Lancet Pub. Group, c2000- |
| مواضيع طبية MeSH: | Biomedical Research* , Brain Neoplasms*/therapy, United States ; Humans ; Quality of Life ; National Cancer Institute (U.S.) ; Consensus |
| مستخلص: | Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient survival, function, and quality of life, mandating a multidimensional approach to clinical care and research. At a virtual National Cancer Institute Workshop in September, 2022, key stakeholders convened to define research priorities to address the crucial areas of unmet need for patients with brain metastases to achieve meaningful advances in patient outcomes. This Policy Review outlines existing knowledge gaps, collaborative opportunities, and specific recommendations regarding consensus priorities and future directions in brain metastases research. Achieving major advances in research will require enhanced coordination between the ongoing efforts of individual organisations and consortia. Importantly, the continual and active engagement of patients and patient advocates will be necessary to ensure that the directionality of all efforts reflects what is most meaningful in the context of patient care. Competing Interests: Declaration of interests TSA, DKS, PSS, JAH, MGE, JSB-S, PGP, CNC, and MMA are employees of the US National Institutes of Health. BME received consulting fees from Medicenna, MedQIA, Servier, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Alpheus Medical, Curtana Pharma, Sagimet Biosciences, and Sapience Therapeutics; and other support from Siemens. SCF received grants from Siemens and Neosoma; consulting fees from Medicenna, MedQIA, Servier, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Alpheus Medical, Curtana Pharma, Sagimet Biosciences, and Sapience Therapeutics; and other services from Siemens. AAA received grants from Varian and NH TheraAguix, and consulting fees from Novartis and Seagen. DMT received grants from Varian Medical Systems, Blue Earth Diagnostics, and NovoCure, and consulting fees from Boston Scientific. RK received grants from Medtronic, Blue Earth Diagnostics, NovoCure, GT Medical Technologies, AstraZeneca, Exelixis, Viewray, Brainlab, and Cantex Pharmaceuticals; consulting fees from Kazia Therapeutics, Elekta, Viewray, Castle Biosciences, and NovoCure; travel support from Elekta, Accuray, NovoCure, and Peerview Institute for Medical Education; other support from Elekta, Accuray, Novocure, and the Peerview Institute for Medical Education; and is on the Viewray Medical Advisory Board. CKA received grants from PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, AstraZeneca, Elucida, and Caris; licences from UpToDate and Jones and Bartlett; other support from Genentech, Eisai, IPSEN, Seattle Genetics, AstraZeneca, Novartis, Immunomedics, Elucida, and Athenex; and is on the Genentech board. PWS received consulting fees from Varian. JH-G has funding from the National Institutes of Health (NIH)/National Cancer Institute (NCI) and received payment for a lecture from Aptitude Health. DNY has a Robert Wood Johnson Foundation Medical Grant and Brockman Foundation Medical Grant. ICGO received grants from Bristol Myers Squibb, Merck, and Pfizer; and consulting fees from Bristol Myers Squibb, Array, Novartis, Sintetica, and Leal Therapeutics. AM received grants from Eisai/H3B Pharmaceutical, Takeda Millenium Pharm, Lilly, Pfizer, MTEM, Merck, Roche, Zion, Norvatis, Dantari, and Genentech; payment from Taiho; research support from Tempus and PUMA; and was on the boards for Seagen and Eli Lilly. EG received grants from Celgene, Denovo Biopharma, MedImmune, and Servier Pharmaceuticals; and is on the boards for Karyopharm Therapeutics, Kiyatec, and Boston Scientific. VG received grants from ImmunoChem Therapeutics. PKB received grants from Mirati, Eli Lilly, Kinnate, Merck, NIH, the Breast Cancer Research Foundation, Damon Runyon, AACR, the Terry and Jean de Gunzburg MGH Research Scholar Fund, and the Demetra fund; consulting fees from Axiom Healthcare, Pfizer, Dantari, Advice Connect inspire, ElevateBio, Sintetica, SK Life Sciences, Voyager Therapeutics, Kazia, MPM Capital, Medscape, Eli Lilly, and Tesaro; other payments from Medscape and Pfizer; other support from GSK, Genentech-Roche, Eli Lilly, AstraZeneca, Kazia, Merck, Mirati, and Pfizer; and was the Chair of Society of Annual Neuro-Oncology Meetings. LC has grants from CDC/Johns Hopkins, DSI, Hological, and Myriad; US patent US7734496B1; stock from UNH; and a leadership role at Touch4Life and MD HBEB. MPM received consulting fees from Kazia, Novocure, Zap, Xoft, Karyopharm, and Sapience; has stocks at Oncoceutics and Chimerix; and is on the boards for Mevion, Oncoceutics, and Xcision. MK received grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, BioNTech, CNS pharmaceuticals, Immorna Therapeutics, Celldex Therapeutics, and Astellas; consulting fees from Novocure and George Clinical; miscellaneous payment from Jax Lab, GSK, Voyager Therapeutics, and Johnson and Johnson; and is on the board for Berg Pharmaceuticals. MSA received grants from Seagen, AstraZeneca, Bristol Myers Squibb, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, and Merck; consulting fees from Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellulartity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Anheart Therapeutics, Varian Medical Systems, Theraguix, and Menarini Ricerche; has stocks from Mimivax, Cytodyn, and Medlnnovate Advisors; and is on the boards for Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences, and Bugworks. MHG has grant number U54CA261717 from the NIH/NCI and received consulting fees from Midatech. JL has research funding from Bristol Myers Squibb. MMK has a grant (number R50CA276015) from the NIH/NCI and Blue Earth Diagnostics; and is on the boards for the NCCN CNS Cancers Guidelines Committee, International Journal of Radiation Oncology*Biology*Physics, Neuro-Oncology, and the External Advisory Board for Stanford U54 MetNet. JR received grants from Black Diamond Therapeutics, Blueprint Medicines, Hummingbird, Merck Sharp & Dohme, Vall d’Hebron Institute of Oncology/Cancer Core Europe, Yingli, AadiBioscience, Amgen, Bayer, Bicycle Therapeutics, BioAtla, BioMed Valley Discoveries, Cellestia, Curis, CytomX, Deciphera, ForeBio, GenMab, GlaxoSmithKline, Hummingbird, Hucthinson MediPharma, Ideaya, Kelun-Biotech, Linnaeus Therapeutics, Loxo Oncology, Merus, Mirati, Novartis, Nuvation, Pfizer, Roche Pharmaceuticals, Spectrum Pharmaceuticals, Symphogen, Taiho, Takeda-Millennium, and Tango Therapeutics; consulting fees from Alnylam Pharmaceuticals, Avoro Capital Advisors, Boxer Capital, the Chinese University of Hong Kong, Clarion Healthcare, Columbus Venture Partners, Cullgen, Debiopharm, Incyte, Macrogenics, Merus, Monte Rosa Therapeutics, Oncology One, Pfizer, Sardona Therapeutics, Tang Advisors, and the Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social; travel support from European Society for Medical Oncology; is on boards for AadiBioscience, Ellipses Pharma, Envision Pharma Limited, Incyte, IONCTURA, Merus, and Monte Rosa Therapeutics; and is on the steering committee for the Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social. AB received support from NIH grant number P30 CA008748, has four US patents, and is on the Evren Technologies Scientific Advisory Board. HT has grants from BMS Bristol Myers Squibb, Novartis, Merck, Genentech, Eisai, GSK, RAPT, and Dragonfly; and received consulting fees from BMS Bristol Myers Squibb, Novartis, Merck, Genentech, Eisai, Iovance, Pfizer, Karyopharm, Boxer Capital, Jazz Pharma, and Medicenna. All other authors declare no competing interests. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| References: | Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411) J Clin Oncol. 2022 Feb 10;40(5):492-516. (PMID: 34932393) Lancet Oncol. 2020 Feb;21(2):e97-e103. (PMID: 32007210) Support Care Cancer. 2012 Apr;20(4):773-81. (PMID: 21479525) J Clin Oncol. 2022 Jul 1;40(19):2163-2171. (PMID: 35588469) Trends Neurosci. 2021 Jun;44(6):441-451. (PMID: 33674135) JAMA Oncol. 2018 Jul 1;4(7):1001-1003. (PMID: 29799956) Neurooncol Pract. 2018 Nov;5(4):214-222. (PMID: 31386015) Neuro Oncol. 2021 Jan 30;23(1):23-33. (PMID: 32623467) Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. (PMID: 30285222) Ann Oncol. 2021 Feb;32(2):171-182. (PMID: 33246022) JCO Oncol Pract. 2023 Jan;19(1):e67-e77. (PMID: 36223556) J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. (PMID: 36509072) Nat Med. 2018 Jul;24(7):1024-1035. (PMID: 29892069) J Clin Oncol. 2022 Aug 10;40(23):2636-2655. (PMID: 35640075) N Engl J Med. 1990 Feb 22;322(8):494-500. (PMID: 2405271) Mol Cancer. 2022 May 10;21(1):113. (PMID: 35538484) Clin Cancer Res. 2023 Jan 4;29(1):174-182. (PMID: 36074155) Oncologist. 2016 Jan;21(1):16-20. (PMID: 26659221) Cancer Discov. 2015 Nov;5(11):1164-1177. (PMID: 26410082) Clin Lung Cancer. 2018 Mar;19(2):139-147. (PMID: 29103883) Breast Cancer Res Treat. 2022 Jan;191(1):209-217. (PMID: 34669082) Neuro Oncol. 2022 Oct 3;24(10):1613-1646. (PMID: 35762249) Curr Opin Oncol. 2019 Nov;31(6):493-500. (PMID: 31414987) Neurooncol Pract. 2021 Jul 13;8(6):662-673. (PMID: 34777835) JCO Oncol Pract. 2022 Nov;18(11):e1732-e1738. (PMID: 36037413) Ann Oncol. 2021 Nov;32(11):1332-1347. (PMID: 34364998) Clin Cancer Res. 2023 Apr 14;29(8):1450-1459. (PMID: 36705597) Nat Rev Cancer. 2011 May;11(5):352-63. (PMID: 21472002) Front Oncol. 2022 Jan 03;11:780379. (PMID: 35047397) Ann Oncol. 2019 Dec 1;30(12):1884-1901. (PMID: 31566661) Ecancermedicalscience. 2020 Nov 05;14:1136. (PMID: 33281928) Neuro Oncol. 2019 Mar 18;21(4):474-485. (PMID: 30615147) Lancet Oncol. 2013 Sep;14(10):e407-16. (PMID: 23993385) Lancet Oncol. 2018 Jan;19(1):e20-e32. (PMID: 29304358) JAMA. 2017 Jul 11;318(2):197-198. (PMID: 28586821) Neuroimage. 2018 Feb 1;166:230-238. (PMID: 29113943) Science. 2003 Dec 5;302(5651):1760-5. (PMID: 14615545) JAMA Oncol. 2022 Sep 1;8(9):1252-1254. (PMID: 35862025) Pract Radiat Oncol. 2022 Jul-Aug;12(4):265-282. (PMID: 35534352) |
| معلومات مُعتمدة: | R01 CA227156 United States CA NCI NIH HHS; R01 CA270027 United States CA NCI NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS; R01 CA279984 United States CA NCI NIH HHS; R50 CA276015 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; P50 CA211015 United States CA NCI NIH HHS; U54 CA261717 United States CA NCI NIH HHS; ZIA BC010538 United States ImNIH Intramural NIH HHS; ZIA BC011330 United States ImNIH Intramural NIH HHS |
| تواريخ الأحداث: | Date Created: 20230804 Date Completed: 20230807 Latest Revision: 20240823 |
| رمز التحديث: | 20240823 |
| مُعرف محوري في PubMed: | PMC10681121 |
| DOI: | 10.1016/S1470-2045(23)00297-8 |
| PMID: | 37541280 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!